Skip to main content

Development of dual-targeting epigenetic modulators for polypharmacology-based cancer therapy

Project description

Multitargeting strategy to overcome cancer therapy resistance

Cancer onset and development is affected by many parameters, including genetics, the environment, and epigenetic factors. As such, compounds that simultaneously target multiple epigenetic enzymes may be a promising therapeutic strategy to overcome cancer therapy resistance. Using this premise, the EU-funded EpiPolyPharma project is developing novel molecules to target protein methylation and acetylation (common in epigenetic pathways). In particular, the researchers are investigating enzymes that cooperate in different pathways simultaneously to counteract tumour growth. As the most promising inhibitors will be assessed in cell assays and for their effects on the regulation of cancer gene transcription, the project foresees additional personalised weapons to combat cancer and related drug resistance.

Funding Scheme

MSCA-PF -

Coordinator

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA
Net EU contribution
€ 172 750,08
Address
Piazzale Aldo Moro 5
00185 Roma
Italy

See on map

Region
Centro (IT) Lazio Roma
Activity type
Higher or Secondary Education Establishments
Other funding
No data

Partners (1)

UNIVERSITA DEGLI STUDI DI PAVIA
Italy
Net EU contribution
€ 0,00
Address
Strada Nuova 65
27100 Pavia

See on map

Region
Nord-Ovest Lombardia Pavia
Activity type
Higher or Secondary Education Establishments
Other funding
No data